Amylyx Pharmaceuticals, Inc.

Healthcare

NASDAQ:AMLX · NASDAQ Global Select

Market Cap $1.27B Beta -0.16 P/E (TTM) -11.3

$15.67 +0.93%

+$0.14 today

52W Low $4.80High $18.61

Vol 1.25M · Avg 1.21M

EPS (TTM) -$1.36Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+212.15%

Period High

$18.36

Period Low

$5.02

Latest

$15.67

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Relay Therapeutics, Inc.

NASDAQ:RLAY

$2.78B

Syndax Pharmaceuticals, Inc.

NASDAQ:SNDX

$1.68B

Atai Beckley Inc.

NASDAQ:ATAI

$1.47B

Precigen, Inc.

NASDAQ:PGEN

$1.39B

Inhibrx Biosciences, Inc.

NASDAQ:INBX

$1.33B

Immatics N.V.

NASDAQ:IMTX

$1.30B

Nektar Therapeutics

NASDAQ:NKTR

$1.16B

CureVac N.V.

CVAC

$1.05B

ORIC Pharmaceuticals, Inc.

NASDAQ:ORIC

$881.47M

Sana Biotechnology, Inc.

NASDAQ:SANA

$844.95M

What is the latest AMLX filing?

The latest filing shown is 4 dated Jun 8, 2026.

How many recent filings does AMLX have?

Intrinsic Alpha currently shows 20 recent filings for AMLX.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.